Select Page

Dr. Leiser has over 10 years of experience in drug discovery and applying translatable neurophysiological biomarkers in diverse drug discovery projects across CNS disorders including schizophrenia, Alzheimer’s, depression, epilepsy. An expert in in vivo electrophysiology, he has established procedures to evaluate multi-unit extracellular neuronal activity or electroencephalography (EEG) and auditory evoked potentials (AEPs), including the rodent correlate of human P300, MMN, and auditory gating (P50, N100) in awake freely-moving animals. He is a specialist in sleep-wake pharmaco-EEG and quantitative EEG in rodent models of disease, including seizure disorders. He has been instrumental in developing translational EEG biomarkers to advance treatments to the clinic during his drug discovery career at Wyeth, AstraZeneca, Lundbeck, and Luc Therapeutics. Dr. Leiser did a postdoctoral fellowship at University of Pennsylvania/CHOP after receiving his Ph.D. in neuroscience from Drexel University College of Medicine.